Amena Iqbal
Amena Iqbal · 3950 HOLLYWOOD RD · Saint Joseph, MI 49085
4.0· 13 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
- Endocrine / metabolic care
About this practice
Amena Iqbal is a practice listed for weight-loss care and endocrine services in Saint Joseph, Michigan, and it offers telehealth visits. On Google it holds a 4.0-star rating across 13 reviews dating back to 2022, with one posted in the past year. Four of those reviews describe the care as caring. No website details were available for this listing, so ask which weight-management options it currently offers.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-06-15. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.0 across 13 Google reviews. Of the 10 reviews we analyzed, 8 (80%) are positive (4–5★) and 2 (20%) are negative (1–2★).
What patients like
- Feeling listened to2 reviews
Common complaints
- Felt rushed or unheard2 of 2 negative
Most recent Google reviews
Sunshine★★★★★2026-06-15My Thyroid was way out of whack when I first went to Dr Iqbal. She worked with me until it was level. She goes out of her way to help. Always responds to me.
Shannon C.★★★★★2025-09-15Dr Igbal, removed my thyroid 3 yrs ago,she don't listen,she doesn't get back with you+ tell me this is the quality of life now) She does care about her patients. Find another Endocrinologist
Sierra S.★★★★★2025-04-23Doctor igbol is a great doctor. She listens carefully to properly diagnose. She goes above and beyond and does great at routinely checking in for follow ups. The explains things throughly
Shaun M.★★★★★2024-09-30Absolutely worst doctor I’ve ever had. Doesn’t want to actually listen. Speaks for you on how your diabetes is. Can’t write the correct prescriptions to save my life. And my life depends on it
Jack G.★★★★★2024-07-02Great, intelligent, very thourough and caring Doctor. Very attentive to detail and great bedside manner. Would give 10 stars if it were possible.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs